Business Context and Reporting Period
Company: Cardinal Health, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2004 (Third Quarter of Fiscal Year 2004)
Business Overview: Cardinal Health operates four primary segments: Pharmaceutical Distribution and Provider Services, Medical Products and Services, Pharmaceutical Technologies and Services, and Automation and Information Services. The company is currently transitioning its pharmaceutical distribution business model from a "buy and hold" inventory strategy to a "just-in-time" fee-for-service model.
Key Financial Metrics
| Metric (in millions) | Three Months Ended Mar 31, 2004 | Nine Months Ended Mar 31, 2004 |
|---|---|---|
| Operating Revenue | $14,638.9 | $42,020.8 |
| Operating Earnings | $664.5 | $1,774.2 |
| Net Earnings | $428.1 | $1,132.5 |
| Diluted EPS | $0.97 | $2.56 |
| Operating Cash Flow (9 months) | $1,335.4 | |
| Cash and Equivalents (Ending) | $527.2 | |
| Total Debt (Current + Long-term) | $2,531.4 |
Note: Debt calculated as Notes payable ($1.2M) + Current portion of long-term obligations ($53.2M) + Long-term obligations ($2,477.0M).
Material Changes vs. Prior Period
- Revenue Growth: Operating revenue increased 14% year-over-year for both the three and nine-month periods, driven by higher sales volume, new customer agreements, and pharmaceutical price increases.
- Earnings Growth: Net earnings rose 12% for the quarter and 9% for the nine-month period. Diluted EPS increased 15% and 12%, respectively, aided by share repurchases.
- Segment Performance:
- Pharmaceutical Distribution: Earnings were flat for the quarter and down 2% for the nine months due to reduced vendor margins associated with the business model transition.
- Medical Products: Operating earnings grew 11% (quarter) and 10% (nine months) due to strong distribution contract momentum.
- Pharmaceutical Technologies: Operating earnings surged 22% (quarter) and 33% (nine months), boosted by the inclusion of the Intercare acquisition (completed Dec 2003) and Syncor (completed Jan 2003).
- Special Items: The company recorded $8.3 million in special item expenses for the quarter and $18.0 million for the nine months, primarily related to merger integration costs (Syncor and Intercare) and restructuring. This compares to $9.8 million expense and $9.1 million income in the prior year periods.
Guidance, Outlook, and Risks
- Business Model Transition: Management expects the transition to a "just-in-time" fee-for-service model to continue impacting vendor margins in the Pharmaceutical Distribution segment, though the most severe impact is believed to have occurred in the prior quarter. This transition is expected to reduce inventory investment and improve long-term operating cash flow.
- Acquisitions: The company completed the acquisition of Intercare Group, plc (approx. $570 million) and other immaterial acquisitions totaling $165 million. Future integration costs are estimated at approximately $85 million.
- Capital Allocation: The company aggressively repurchased shares, spending $1.46 billion in the nine-month period. A $500 million accelerated share repurchase program was initiated in Q3, with approximately $460 million executed by quarter-end.
- Legal and Regulatory Risks:
- SEC Investigation: The SEC converted an informal inquiry into a formal investigation regarding the accounting treatment of $22 million recovered from vitamin manufacturers. An internal audit committee review is ongoing.
- Syncor Litigation: Multiple shareholder lawsuits and Department of Labor investigations remain pending regarding alleged improper payments by Syncor prior to acquisition. Management believes these will not have a material adverse effect.
- Latex Litigation: Ongoing lawsuits regarding natural rubber latex gloves; potential liability estimated between $0 and $20 million net of insurance.
- Market Risk: Foreign currency exposure increased due to the Intercare acquisition. A hypothetical 10% currency fluctuation could result in a net gain/loss of approximately $14.9 million after hedging.
Investor Verification Checklist
- Business Model Impact: Verify the timeline and financial impact of the transition from "buy and hold" to "just-in-time" distribution on gross margins.
- SEC Investigation Status: Monitor updates regarding the formal SEC investigation into vitamin manufacturer recovery accounting.
- Syncor Integration Costs: Track the realization of the estimated $85 million in future merger and restructuring costs.
- Share Repurchase Settlement: Confirm the final settlement price and share count for the accelerated share repurchase program (expected Q4 2004).
- Intercare Integration: Assess the performance of the newly acquired Intercare operations within the Pharmaceutical Technologies segment.